PBYI vs RCUS vs EXEL vs TGTX vs INCY

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Puma Biotechnology, Inc. (PBYI) offers the better valuation at 12. 3x trailing P/E (30. 0x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Puma Biotechnology, Inc.

(PBYI) is the cheapest at 12. 3x versus Exelixis, Inc. at 17. 3x. On forward P/E, Incyte Corporation is actually cheaper at 13. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +93. 0%, compared to -19. 0% for Puma Biotechnology, Inc. (PBYI). Over 10 years, the gap is even starker: EXEL returned +872. 9% versus PBYI's -69. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 84β versus Arcus Biosciences, Inc. 's 1. 84β — meaning RCUS is approximately 120% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 40% for TG Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.

1x forward P/E versus 32. 9x for TG Therapeutics, Inc. — 19. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TGTX: 27. 2% to $54. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +872. 9% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXEL: +872. 9%, RCUS: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PBYI is a small-cap deep-value stock; RCUS is a small-cap quality compounder stock; EXEL is a mid-cap deep-value stock; TGTX is a small-cap high-growth stock; INCY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.